- Home
- MDRR vs NXL Comparison
MDRR vs NXL Comparison
Compare MDRR & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- NXL
- Stock Information
- Founded
- MDRR 2015
- NXL 2010
- Country
- MDRR United States
- NXL United States
- Employees
- MDRR N/A
- NXL N/A
- Industry
- MDRR Real Estate Investment Trusts
- NXL Medical Specialities
- Sector
- MDRR Real Estate
- NXL Health Care
- Exchange
- MDRR Nasdaq
- NXL Nasdaq
- Market Cap
- MDRR 17.1M
- NXL 17.8M
- IPO Year
- MDRR 2018
- NXL 2022
- Fundamental
- Price
- MDRR $13.15
- NXL $0.93
- Analyst Decision
- MDRR
- NXL Strong Buy
- Analyst Count
- MDRR 0
- NXL 1
- Target Price
- MDRR N/A
- NXL $5.00
- AVG Volume (30 Days)
- MDRR 2.0K
- NXL 191.8K
- Earning Date
- MDRR 11-11-2025
- NXL 11-07-2025
- Dividend Yield
- MDRR 2.03%
- NXL N/A
- EPS Growth
- MDRR N/A
- NXL N/A
- EPS
- MDRR N/A
- NXL N/A
- Revenue
- MDRR $9,649,145.00
- NXL $174,813.00
- Revenue This Year
- MDRR N/A
- NXL $38.28
- Revenue Next Year
- MDRR N/A
- NXL $185.71
- P/E Ratio
- MDRR N/A
- NXL N/A
- Revenue Growth
- MDRR N/A
- NXL 16.42
- 52 Week Low
- MDRR $9.55
- NXL $0.59
- 52 Week High
- MDRR $15.00
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- MDRR 50.62
- NXL 52.06
- Support Level
- MDRR $13.05
- NXL $0.86
- Resistance Level
- MDRR $14.00
- NXL $0.97
- Average True Range (ATR)
- MDRR 0.31
- NXL 0.08
- MACD
- MDRR -0.10
- NXL 0.00
- Stochastic Oscillator
- MDRR 11.07
- NXL 48.80
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.